Vaxinano Highlights In Ovo Nanovaccine Advancement for Poultry Health

According to a recent LinkedIn post from Vaxinano, the company is highlighting a new peer‑reviewed publication in MDPI Animals describing a trivalent inactivated in ovo nanovaccine targeting avian colibacillosis in broiler chickens. The post characterizes this as the first report of an inactivated in ovo vaccine for this indication, emphasizing strong immunogenicity, compatibility with commonly used live viral vaccines, and scalability via the firm’s nanovaccine platform.

The LinkedIn post suggests that in ovo vaccination could provide earlier and more uniform immunity in commercial hatcheries while reducing labor and handling, which may appeal to large poultry producers focused on operational efficiency. By positioning the technology as a tool to help address antimicrobial resistance through preventive vaccination, the post indicates a potential alignment with global policy trends that favor reduced antibiotic use in livestock.

From an investor perspective, the publication may enhance Vaxinano’s scientific credibility and strengthen its platform narrative in veterinary vaccines, particularly in the high‑volume poultry segment. If the approach proves commercially viable and compatible with existing hatchery infrastructure, it could open licensing, partnership, or co‑development opportunities with vaccine manufacturers and integrated poultry producers.

The acknowledgment of support from the International Development Research Centre’s InnoVet AMR 1.0 program also points to external interest in the technology’s role in combating antimicrobial resistance. Continued grant backing and validation in peer‑reviewed journals could de‑risk early‑stage R&D and improve the company’s positioning for future fundraising or strategic collaborations in both animal health and broader nanovaccine applications.